GlassScriptPhysician profile
Sandeep Jaglan
NPI 1205872116
$3,856.95
in general payments reported to CMS, 2019-2025
28 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $169 · 2021: $280 · 2022: $191 · 2023: $2,168 · 2024: $111 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.62 |
| Education | $190.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.50 | 2019-2023 | Lokelma, Farxiga, Evusheld |
| Bayer Healthcare Pharmaceuticals INC. | $479.63 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $326.10 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $310.00 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $288.60 | 2020-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $230.77 | 2019-2023 | Velphoro |
| Amgen INC. | $176.15 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Travere Therapeutics, INC. | $176.09 | 2020-2023 | |
| Calliditas Therapeutics US INC. | $169.52 | 2023-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $155.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $130.42 | 2023-2025 | |
| Vifor Pharma, INC. | $123.53 | 2019-2023 | Korsuva, Veltassa |
| Novo Nordisk INC | $113.42 | 2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $82.56 | 2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $66.43 | 2019-2023 | Ultomiris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $65.56 | 2019 | |
| Akebia Therapeutics INC | $60.41 | 2019-2024 | Vafseo |
| Opko Pharmaceuticals, LLC | $57.25 | 2023 | Rayaldee |
| Alnylam Pharmaceuticals INC. | $46.12 | 2023 | Onpattro, Oxlumo |
| Daiichi Sankyo INC. | $41.17 | 2019-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.58 | 2023 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $29.50 | 2019 | |
| Lilly USA, LLC | $20.79 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $19.84 | 2022 | |
| Genzyme Corporation | $19.74 | 2019 | |
| Merck Sharp & Dohme LLC | $16.03 | 2023 | Prevymis |
| Amag Pharmaceuticals, INC. | $15.10 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Jaglan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.